BiopharmaWatch - FDA Calendar, PDUFA Calendar & Biotech Catalyst Tracker

Free FDA Calendar, PDUFA Calendar & biotech catalyst tracker. Real-time drug approval dates, clinical trial readouts, insider trades, hedge fund holdings & market-moving catalysts for biotech investors.

www.biopharmawatch.com

BiopharmaWatch - FDA Calendar, PDUFA Calendar & Biotech Catalyst Tracker · 18 hrs ago

HEALTH AND WELLNESS

Phase 2a Trial for GlyphAgo™ Begins with First Patient - SPTX

Seaport Therapeutics has dosed its first patient in a Phase 2a trial for GlyphAgo™, targeting anxiety and sleep issues.

BOSTONGLYPH AGO™PURE TECH

BiopharmaWatch - FDA Calendar, PDUFA Calendar & Biotech Catalyst Tracker · 19 hrs ago

BIOLOGY AND BIOTECHNOLOGY

Genmab Approves 2026 Board Remuneration - GMAB

Genmab A/S approved a remuneration proposal for 2026, granting 5,300 restricted stock units to board members.

NORTH AMERICAASIA PACIFICIMMUNE MODULATING ANTIBODIESGENMAB

BiopharmaWatch - FDA Calendar, PDUFA Calendar & Biotech Catalyst Tracker · 22 hrs ago

BIOLOGY AND BIOTECHNOLOGY

Rocket Pharmaceuticals Updates on FDA-Aligned Trial - RCKT

Rocket Pharmaceuticals updates on its pivotal Phase 2 trial for RP-A501, highlighting key findings from the Danon disease webinar.

USEUROCKET PHARMACEUTICALSROCKET PHARMACEUTICALS INCNASDAQ

BiopharmaWatch - FDA Calendar, PDUFA Calendar & Biotech Catalyst Tracker · 22 hrs ago

HEALTH AND WELLNESS

Exploring Ampligen's Role in Pancreatic Cancer - AIM

AIM ImmunoTech's strategy for pancreatic cancer highlights Ampligen's potential as a maintenance therapy post-chemotherapy.

UNITED STATESEUROPEAN UNIONFOLFIRINOXAIM IMMUNO TECH INC

BiopharmaWatch - FDA Calendar, PDUFA Calendar & Biotech Catalyst Tracker · 22 hrs ago

HEALTH AND WELLNESS

BioCardia Unveils CardiAMP HF II Trial at HFSA Meeting - BCDA

BioCardia presents the CardiAMP HF II trial design at HFSA 2026, focusing on ischemic heart failure treatment. FDA category B designation granted.

AZJAPANCARDI ALLO™ ALLOGENEIC CELL THERAPIESPETER ALTMAN